What is Genemod?
Genemod provides life scientists and researchers with advanced cloud-based solutions for inventory and product management, aiming to maximize productivity within biotech companies. Their platform facilitates collaboration, streamlines reagent inventory, and optimizes workflows, thereby driving the development of cutting-edge therapies. Genemod's vision is to empower organizations to accelerate the discovery of cures by offering sophisticated pre-clinical software, supporting leading biotech institutions like the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine.
How much funding has Genemod raised?
Genemod has raised a total of $7.7M across 3 funding rounds:
Other Financing Round
$1.5M
Angel/Seed
$1.7M
Angel/Seed
$4.5M
Other Financing Round (2020): $1.5M, investors not publicly disclosed
Angel/Seed (2020): $1.7M led by Canaan Partners, Unpopular Ventures, Defy.vc, Omicron, and Underdog Labs
Angel/Seed (2023): $4.5M supported by LDV Partners, Vulcan Medical Ventures, Dolby Family Ventures, and Defy
Key Investors in Genemod
Canaan Partners
Canaan Partners is an early-stage venture capital firm specializing in technology and healthcare, supporting companies from seed to growth stages in areas like enterprise software and biopharma.
LDV Partners
LDV Partners is dedicated to transforming innovative ideas into successful companies by collaborating closely with visionary founders, providing strategic insights and resources to foster growth in disruptive technologies.
Vulcan Medical Ventures
Vulcan Medical Ventures is a venture capital firm focused on identifying significant investment opportunities in the biomedical markets, providing seed, start-up, and early-stage financing to emerging biotechnology companies.
What's next for Genemod?
The substantial enterprise-level capital infusion positions Genemod for significant scaling and further innovation in its cloud-based solutions for the biotech sector. With a recent strategic investment, the company is poised to expand its market reach and enhance its technological offerings. This backing will likely fuel advancements in their pre-clinical software, enabling more biotech firms to collaborate effectively and expedite the research and development of novel therapies. Genemod's trajectory suggests a focus on solidifying its role as a critical technology partner in the pursuit of faster cures.
See full Genemod company page
